The MDS Beacon Staff's Archive

The MDS Beacon Staff has written 25 article(s).

[ by and | Sep 16, 2009 12:04 pm | Comments Off ]
H1N1 Swine Flu Vaccinations Recommended For Patients With Myelodysplastic Syndromes

The United States Centers for Disease Control (CDC) has begun a vaccination campaign against both the seasonal influenza virus and the H1N1 (swine flu) virus. Patients with myelodysplastic syndromes (MDS) are recommended to receive both flu shots, in addition to a vaccine for pneumonia for flu-related complications. The flu shots may be administered simultaneously at different injection sites on the body.

The H1N1 flu, originally known as the swine flu, is responsible for thousands of hospitalizations and more than 170…

Tags: ,
Read the full story »
[ by | Aug 13, 2009 4:33 pm | Comments Off ]
Beacon NewsFlashes – August 13, 2009

Seattle Genetics Raises Funds For Research – Seattle Genetics announced that it is increasing its cash by approximately $118.2 million through the issuance of common stock. The funds will be used, among other things, for research and development, including clinical trials. The company has several compounds under development for the treatment of blood cancers. In particular, they are conducting clinical trials for lintuzumab (SGN-33), which has received orphan drug status from the FDA for the treatment of acute myeloid leukemia…

Tags: ,
Read the full story »
[ by | Aug 6, 2009 8:00 pm | Comments Off ]
Beacon SiteUpdate – The MDS Beacon Has A New Design

We are proud to present a new design for The MDS Beacon.

The layout of the home page has been changed to put the emphasis on headline news and featured articles. We have added color photos to our articles to make them more visually appealing.

The new design also includes an enhanced stream of the most recent activity. You can follow the most recent, most popular, and most commented news, resources, and links right at the home page.

Previously…

Tags: ,
Read the full story »
[ by | Jul 13, 2009 11:57 am | Comments Off ]

At the 14th Congress of the European Hematology Association (EHA), researchers from several South Korean hospitals presented a two year study in which they analyzed the outcome of Vidaza (azacitidine) treatments in myelodysplastic syndromes (MDS) patients who had a variety of pretreatment risk assessments. Their results indicated that patients’ pretreatment risk groups were a significant factor in predicting their response to this treatment.

Before starting any type of treatment, patients are assessed and analyzed so that doctors can determine the…

Tags: , ,
Read the full story »